How to Read a Clinical Trial of Injectables

A clinical trial is, in theory, the best tool for knowing whether an injectable does what it promises. In practice, the level of confidence varies a great deal from one trial to another, and what separates a useful study from a decorative one lies in details the abstract rarely highlights: what was measured, who measured it, who knew what, and who paid.

This page offers a reading roadmap for the orofacial harmonization (HOF) professional, focused on three points that often decide the quality of an injectable trial: the outcome, blinding, and conflict of interest. It complements how to keep up with the scientific literature and levels of evidence in HOF. It does not cite specific studies or present result figures: the goal is to train the eye.

What is the study's question?

Start at the end of the abstract or the last sentence of the introduction: what question does the study want to answer? In injectable trials, the typical questions are:

• is product A better than no treatment or placebo for a given area?
• is product A equivalent to product B (a non-inferiority study)?
• what is the duration of the effect and the frequency of adverse events?

If you cannot state the question in one sentence, the study is probably poorly designed, or the abstract is written to sell. A good trial has a clear question, a hypothesis defined before the start, and prior registration, when available, to show the outcome was not switched along the way.

How do you read the outcome?

The outcome is the measure that will say whether the product "worked". Two points deserve attention.

Primary or secondary. The primary outcome is the one defined as the main one; secondary outcomes are complementary. A study that fails on the primary and highlights the secondary is trying to rescue the narrative.

Who measures and how. In aesthetics, the outcome can be:

Prefer studies that combine more than one type of outcome and use validated scales. To understand these tools, read validated aesthetic assessment scales and FACE-Q and patient-reported outcomes.

What is blinding and why does it weigh so much?

Blinding means preventing someone from knowing which treatment was applied. There are different levels:

• Single-blind: the patient does not know what they received.
• Double-blind: neither patient nor assessor knows.
• Blinded assessor: the person injecting knows (unavoidable in many injectable techniques), but the person assessing photos and scales does not.

With injectables, blinding the person who injects is hard, because products have different textures and techniques. That is why blinding the assessor is the most important point. Ask: who scored the photos? Did that person know the group? Were the photos shuffled and assessed by more than one observer? When this information is missing, the aesthetic score may reflect expectation, not result.

The "split-mouth" or "split-face" design, in which each side receives a different product, helps compare within the same patient, but it has limits: natural asymmetries and neighboring effects can interfere. Read the methods section to see how the study handled this.

Who took part and what does that say about your patient?

The study population defines whom the result applies to. Look at:

• predominant age and sex;
• skin types and ethnicities represented;
• exclusion criteria (many studies exclude precisely the complex patients you treat);
• where it was carried out and the number of injectors;
• sample size and percentage lost to follow-up.

If the study was done in a group that does not resemble your patient, the result serves as a reference, not as a prediction. Older patients, those with thinner skin, or those with comorbidities may respond differently. For profile-based reasoning, see HOF in patients over 50 and HOF in dark skin.

How long were the patients followed?

Follow-up is one of the most fragile points in the aesthetics literature. Many trials end after a few months, but the patient wants to know what happens afterward. Late adverse events, such as nodules and delayed reactions, only appear with longer follow-up. A phrase like "well tolerated" in a short study says little about long-term safety.

Likewise, claims about duration of effect require matching follow-up. Be wary of conclusions that go beyond the period observed. On filler duration, see real duration of hyaluronic acid in the face.

Conflict of interest: how do you read that statement?

Look for the conflict of interest statement and the funding source, usually at the end of the paper. When the manufacturer funds the study, pays the authors, or supplies the product, this does not invalidate the study, but it increases the need to check:

• whether the comparator was fair (appropriate dose, technique, and comparison product);
• whether the complete data are accessible, including negative outcomes;
• whether the outcome was the same one registered before the start;
• whether independent studies confirm it.

The problem worsens with publication bias, in which negative studies are less likely to be published. See publication bias in aesthetics.

How do you turn reading into practice?

A well-conducted trial helps you decide, but it does not decide for you. The prudent path is:

1. classify the study (high, medium, or low weight) using the criteria above;
2. compare it with what you already practice and with the product's instructions for use (see how to read an injectable's instructions for use);
3. decide between adopting, watching, or discarding, recording the reason;
4. if you adopt, inform the patient without promising more than the data support.

Harmy does not do this work for you. It comes in after the clinical decision, helping you talk with the patient through an illustrative projection made from a frontal photo. The projection is an illustrative simulation, not a promise of results: it is not evidence of a result and should not be presented as such.